

3M CO

FORM 10-Q (Quarterly Report)

Filed 05/10/99 for the Period Ending 03/31/99

Address	3M CENTER BLDG. 220-11W-02 ST PAUL, MN 55144-1000
Telephone	6517332204
CIK	0000066740
Symbol	MMM
SIC Code	3841 - Surgical and Medical Instruments and Apparatus
Industry	Constr. - Supplies & Fixtures
Sector	Capital Goods
Fiscal Year	12/31

3M CO

FORM 10-Q (Quarterly Report)

Filed 5/10/1999 For Period Ending 3/31/1999

Address	3M CENTER BLDG. 220-11W-02 ST PAUL, Minnesota 55144-1000
Telephone	651-733-2204
CIK	0000066740
Industry	Conglomerates
Sector	Conglomerates
Fiscal Year	12/31

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 10-Q

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

For Quarter ended March 31, 1999 Commission file number: 1-3285

**MINNESOTA MINING AND MANUFACTURING
COMPANY**

State of Incorporation: Delaware
I.R.S. Employer Identification No. 41-0417775

Executive offices: 3M Center, St. Paul, Minnesota 55144

Telephone number: (651) 733-1110

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No .

On March 31, 1999, there were 402,639,206 shares of the Registrant's common stock outstanding.

This document contains 29 pages.

The exhibit index is set forth on page 26.

Minnesota Mining and Manufacturing Company and Subsidiaries

PART I. Financial Information

Consolidated Statement of Income
 (Amounts in millions, except per-share amounts)
 (Unaudited)

	Three months ended	
	March 31	
	1999	1998
Net sales	\$3,776	\$3,700
Operating expenses		
Cost of goods sold	2,162	2,096
Selling, general and administrative expenses	965	924
Total	3,127	3,020
Operating income	649	680
Other income and expense		
Interest expense	31	34
Investment and other income - net	(8)	(11)
Total	23	23
Income before income taxes and minority interest	626	657
Provision for income taxes	225	237
Minority interest	17	20
Net income	\$ 384	\$ 400
Weighted average common shares outstanding	402.3	404.4
Earnings per share - basic	\$.95	\$.99
Weighted average common and common equivalent shares outstanding	405.9	410.0
Earnings per share - diluted	\$.95	\$.98

<F1>

The accompanying Notes to Consolidated Financial Statements
 are an integral part of this statement.

Minnesota Mining and Manufacturing Company and Subsidiaries
Consolidated Balance Sheet
(Dollars in millions)

	(Unaudited)	
	March 31, 1999	December 31, 1998
Assets		
Current assets		
Cash and cash equivalents	\$ 253	\$ 211
Other securities	98	237
Accounts receivable - net	2,647	2,666
Inventories		
Finished goods	1,147	1,161
Work in process	538	613
Raw materials and supplies	407	445
Total inventories	2,092	2,219
Other current assets	966	985
Total current assets	6,056	6,318
Investments	639	623
Property, plant and equipment	13,275	13,397
Less accumulated depreciation	(7,759)	(7,831)
Property, plant and equipment - net	5,516	5,566
Other assets	1,535	1,646
Total	\$13,746	\$14,153
Liabilities and Stockholders' Equity		
Current liabilities		
Accounts payable	\$ 913	\$ 868
Payroll	438	487
Income taxes	418	261
Short-term debt	1,151	1,492
Other current liabilities	1,062	1,278
Total current liabilities	3,982	4,386
Other liabilities	2,226	2,217
Long-term debt	1,569	1,614
Stockholders' equity		
Common stock, \$.50 par value, 472,016,528 shares issued	236	236
Capital in excess of par value	60	60
Retained earnings	10,121	9,980
Treasury stock, at cost	(3,430)	(3,482)
March 31, 1999, 69,377,322		
December 31, 1998, 70,092,280		
Unearned compensation - ESOP	(337)	(350)
Accumulated other comprehensive income		
Cumulative translation - net	(702)	(518)
Debt and equity securities, unrealized gain - net	21	10
Total accumulated other comprehensive income	(681)	(508)
Stockholders' equity - net	5,969	5,936
Total	\$13,746	\$14,153

<F1>

The accompanying Notes to Consolidated Financial Statements are an integral part of this statement.

Minnesota Mining and Manufacturing Company and Subsidiaries

Consolidated Statement of Cash Flows
(Dollars in millions)
(Unaudited)

	Three months ended	
	March 31	
	1999	1998
Cash Flows from Operating Activities		
Net income	\$ 384	\$ 400
Adjustments to reconcile net income to net cash provided by operating activities		
Depreciation and amortization	223	213
Implant litigation - net	(30)	(91)
Working capital and other changes - net	251	(147)
Net cash provided by operating activities	828	375
Cash Flows from Investing Activities		
Capital expenditures	(289)	(338)
Other changes - net	(40)	(63)
Net cash used in investing activities	(329)	(401)
Cash Flows from Financing Activities		
Change in short-term debt - net	(136)	(55)
Repayment of long-term debt	(104)	(20)
Proceeds from long-term debt	--	333
Purchases of treasury stock	(32)	(187)
Reissuances of treasury stock	67	127
Payment of dividends	(225)	(222)
Net cash used in financing activities	(430)	(24)
Effect of exchange rate changes on cash	(27)	--
Net increase (decrease) in cash and cash equivalents	42	(50)
Cash and cash equivalents at beginning of year	211	230
Cash and cash equivalents at end of period	\$ 253	\$ 180

<F1>

The accompanying Notes to Consolidated Financial Statements
are an integral part of this statement.

Notes to Consolidated Financial Statements

(Unaudited)

The interim consolidated financial statements are unaudited but, in the opinion of management, reflect all adjustments necessary for a fair presentation of financial position, results of operations and cash flows for the periods presented. These adjustments consist of normal, recurring items. The results of operations for any interim period are not necessarily indicative of results for the full year. The interim consolidated financial statements and notes are presented as permitted by the requirements for Form 10-Q and do not contain certain information included in the company's annual consolidated financial statements and notes. This Form 10-Q should be read in conjunction with the company's consolidated financial statements and notes included in its 1998 Annual Report on Form 10-K.

Pending Divestitures:

The company has entered into agreements to sell Eastern Heights Bank, a subsidiary banking operation, to Norwest Bank Minnesota (a subsidiary of Wells Fargo & Company), and to sell the assets of its Cardiovascular Systems business to Terumo Corp. of Tokyo, Japan. These divestitures, expected to be finalized late in the second quarter or early in the third quarter of 1999, should generate cash proceeds (net of tax) of approximately \$185 million.

Restructuring Charge:

In 1998, the company recorded a restructuring charge of \$493 million (\$313 million after tax), which is discussed in the 1998 Form 10-K. During the quarter ended March 31, 1999, the company terminated 688 employees under the plan. Because certain employees can defer receipt of termination benefits for up to 12 months, cash payments relate to both current and previous terminations. The restructuring liability as of March 31, 1999, totaled \$198 million. Selected information relating to the restructuring charge follows.

Restructuring Information (Millions)	Employee Termination Benefits	Other	Total
Restructuring liability as of December 31, 1998	\$232	\$32	\$264
1999 cash payments First quarter	(65)	(1)	(66)
Restructuring liability as of March 31, 1999	\$167	\$31	\$198

Business Segments:

Net sales and operating income by segment for the first quarter of 1999 and first quarter of 1998 follow.

Business Segment Information (Millions)	Industrial and Consumer	Transportation, Safety and Specialty Material	Health Care	Corporate and Unallocated	Total Company
Net sales					
First Quarter 1999	\$1,922	\$1,069	\$768	\$ 17	\$3,776
First Quarter 1998	1,906	1,017	759	18	3,700
Operating income					
First Quarter 1999	\$ 322	\$ 207	\$142	\$(22)*	\$ 649
First Quarter 1998	314	192	151	23 *	680

Due to changes in cost allocations among segments, total year 1998, 1997 and 1996 sales and operating income have been restated as follows.

Business Segment Information (Millions)		Industrial and Consumer	Transportation, Safety and Specialty Material	Health Care	Corporate and Unallocated	Total Company
Net sales						
1998	1998	\$7,714	\$4,126	\$3,086	\$ 95	\$15,021
1997	1997	7,774	4,202	3,004	90	15,070
1996	1996	7,377	3,896	2,897	66	14,236
Operating income						
1998	1998	\$1,223	\$ 719	\$ 571	\$(474)*	\$ 2,039
1997	1997	1,309	774	521	71 *	2,675
1996	1996	1,194	778	545	(26)*	2,491
Assets**						
1998	1998	\$5,185	\$3,764	\$2,168	\$3,036	\$14,153
1997	1997	5,030	3,296	2,042	2,870	13,238
1996	1996	4,771	3,129	2,012	3,452	13,364
Depreciation and amortization						
1998	1998	\$ 446	\$ 236	\$ 161	\$ 23	\$ 866
1997	1997	405	261	183	21	870
1996	1996	425	270	160	28	883
Capital expenditures						
1998	1998	\$ 676	\$ 517	\$ 221	\$ 16	\$ 1,430
1997	1997	581	563	217	45	1,406
1996	1996	430	445	216	18	1,109

<F1>

*Corporate and Unallocated operating income principally includes corporate investment gains and losses, certain derivative gains and losses, insurance related gains and losses, banking operations, restructuring charges and other miscellaneous items. Since this category includes a variety of miscellaneous items, it is subject to fluctuation on a quarterly and annual basis. Operating income for 1998 includes a \$493 million restructuring charge.

<F2>

**Segment assets primarily include accounts receivable; inventory; property, plant and equipment - net; and other miscellaneous assets. Assets included in Corporate and Unallocated principally are cash and cash equivalents; other securities; insurance receivables; deferred income taxes; certain investments and other assets; and certain unallocated property, plant and equipment.

Comprehensive income:

The components of total comprehensive income are shown below.

Total Comprehensive Income (Millions)	Three months ended March 31,	
	1999	1998
Net income	\$ 384	\$ 400
Other comprehensive income		
Cumulative translation - net Debt and equity securities, unrealized gain (loss) - net	\$ (184)	\$ (42)
Total comprehensive income	\$ 211	\$ 357

Earnings per share:

The difference in the weighted average shares outstanding for calculating basic and diluted earnings per share is attributable to the assumed exercise of the Management Stock Ownership Program (MSOP) stock options for the three-month periods ended March 31, 1999 and 1998. MSOP options to purchase 11.2 million shares of common stock at an average price of \$91.59, which were outstanding at March 31, 1999, were not included in the computation of diluted earnings per share because they would not have had a dilutive effect.

Other:

Discussion of legal matters is cross-referenced to this Form 10-Q, Part II, Item 1, Legal Proceedings, and should be considered an integral part of the interim consolidated financial statements.

PricewaterhouseCoopers LLP, the company's independent auditors, have performed a review of the unaudited interim consolidated financial statements included herein and their review report thereon accompanies this filing.

Review Report of Independent Auditors

To the Stockholders and Board of Directors of Minnesota Mining and Manufacturing Company:

We have reviewed the accompanying consolidated balance sheet of Minnesota Mining and Manufacturing Company and Subsidiaries as of March 31, 1999, and the related consolidated statements of income and cash flows for the three-month periods ended March 31, 1999 and 1998. These financial statements are the responsibility of the Company's management.

We conducted our reviews in accordance with standards established by the American Institute of Certified Public Accountants. A review of interim financial information consists principally of applying analytical procedures to financial data and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with generally accepted auditing standards, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the consolidated financial statements referred to above for them to be in conformity with generally accepted accounting principles.

We have previously audited, in accordance with generally accepted auditing standards, the consolidated balance sheet as of December 31, 1998, and the related consolidated statements of income, changes in stockholders' equity and comprehensive income, and cash flows for the year then ended (not presented herein); and in our report dated February 8, 1999, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of December 31, 1998, is fairly stated in all material respects in relation to the consolidated balance sheet from which it has been derived.

/s/ PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP

*St. Paul, Minnesota
May 5, 1999*

Minnesota Mining and Manufacturing Company and Subsidiaries

Management's Discussion and Analysis of Financial Condition and Results of Operations

RESULTS OF OPERATIONS

First Quarter

Worldwide sales for the first quarter totaled \$3.776 billion, up 2.1 percent from the first quarter last year. Volume increased about 2

percent, while selling prices were up about 1 percent. Currency translation reduced worldwide sales by about 1 percent. Currency, while positive in the Asia Pacific area, was negative in other parts of the world, especially Latin America.

In the United States, sales increased about 2 percent to \$1.768 billion, driven by volume increases. In Transportation, Safety and Specialty Material Markets, U.S. volume increased about 4 percent. Within this business segment, the company saw good growth in its commercial graphics, protective materials and roofing granule businesses, and a pickup in demand for reflective products following a soft 1998. In Industrial and Consumer Markets, led by the consumer and office businesses, volume increased nearly 3 percent. Demand for certain industrial products, including tapes and abrasives, remained soft. Volume in the U.S. health care businesses declined about 3 percent from the year-earlier quarter. Sales of medical and dental products experienced good growth, but sales of pharmaceuticals declined due to the introduction of generic alternatives to a branded 3M analgesic. The largest effects of this competition will extend through the third quarter of 1999.

Internationally, sales totaled \$2.008 billion. Volume abroad increased about 2.5 percent, while selling prices were up about 2 percent, resulting in overall local-currency sales gains of about 4.5 percent. Currency translation reduced international sales by about 2 percent. In Europe, volume increased less than 1 percent. Sales were impacted by economic slowing in Western Europe and by the uncertainty in developing European countries. Also, the company is comparing against its strongest quarter in Europe last year. In the Asia Pacific area, volume increased about 7 percent, the company's best performance in five quarters. In Japan, unit sales rose 5 percent, despite continuing economic weakness. In Asia outside Japan, volume rose about 12 percent. 3M experienced sharp volume rebounds in Korea, Thailand and Indonesia, and good growth in the China region. In Latin America, volume was roughly the same as in the first quarter last year. While unit sales increased more than 10 percent in Mexico, volume was flat in Argentina and unit sales declined about 7 percent in Brazil. The company increased selling prices in Latin America about 7 percent. Currency translation, largely due to Brazilian devaluation, reduced Latin American sales by about 20 percent. In Canada, volume increased more than 10 percent.

Worldwide, the Industrial and Consumer market sales and operating income growth was led by the consumer and office businesses. Transportation, Safety and Specialty Material segment sales and

operating income growth was led by films for laptop computers and other electronic displays, and by protective materials. Health Care showed good growth in medical and dental, but was hurt by declines in pharmaceuticals.

Cost of goods sold, which includes manufacturing, research and development, and engineering, was 57.3 percent of sales, up seven-tenths of a percentage point from the first quarter last year. However, this was down more than 2 percentage points from the fourth quarter and was an improvement of more than half a percentage point from the rate the company averaged for 1998 as a whole. Gross margins benefited from lower raw material costs and the company's restructuring actions.

Selling, general and administrative spending was 25.5 percent of sales, higher than the company's target. For the full year 1999, the company expects this spending to be below 25 percent of sales, helped by productivity gains stemming from restructuring actions, and by continuing spending discipline.

Worldwide operating income was 17.2 percent of sales, down 1.2 percentage points from the first quarter last year. While lower than the first quarter last year, this represented an improvement from each of the past three quarters and from 1998 in total. In dollars, operating income declined 4.4 percent from the same quarter last year.

First quarter interest expense of \$31 million was down \$3 million from the same quarter last year. Net investment and other income was \$8 million, in line with recent trends.

The worldwide effective income tax rate for the quarter was 36.0 percent, the same as in the first quarter last year.

Net income totaled \$384 million, or \$.95 per diluted share, compared with \$400 million, or \$.98 per diluted share, in the first quarter of 1998. The company estimates that changes in the value of the U.S. dollar decreased earnings for the quarter by about 2 cents per share compared with the first quarter of 1998. This estimate includes the effect of translating profits from local currencies into U.S. dollars; the impact of currency fluctuations on the transfer of goods between 3M operations in the United States and abroad; and transaction gains and losses.

FUTURE OUTLOOK

The company encountered a difficult set of challenges in 1998 - large negative currency effects, economic contractions in many international markets, and softness in a few key U.S. markets. To improve productivity and reduce costs, the company is exiting certain product lines, consolidating manufacturing operations, and eliminating lower-value activities in corporate service functions. Relating to these actions, the company recorded a restructuring charge in 1998. This charge is discussed in the 1998 Form 10-K.

The company announced in mid-1998, as part of its restructuring plan, its intent to reduce about 4,500 positions by December 31, 1999. The majority of these reductions are expected by September 30, 1999. During the quarter, employment declined approximately 1,100 people due to both the restructuring and attrition, bringing the total reductions thus far to 3,500 people. These reductions have been about equally divided between U.S. and international operations.

When fully implemented by the end of 1999, the restructuring plan is expected to provide annual pre-tax savings of about \$250 million. The company anticipates implementation costs associated with this restructuring plan to be about \$35 million in 1999. These costs, not included in the 1998 restructuring charge, include expenses for relocating employees, inventory and equipment; unfavorable overhead variances; and other expenses. If the company does not generate adequate sales growth, normal increases in salaries and wages and additional depreciation from capital expenditures will create offsets to the annual savings.

3M expects sales growth in 1999 of 4 to 5 percent in local currencies. Sales are expected to grow 3 to 4 percent in the United States. Sales growth in the U.S. is expected to pick up in the remaining three quarters of this year. Internationally, the company is expecting to increase sales in local currencies 5 to 6 percent. The company expects continuing reasonable volume growth in the Asia region. Asia appears to be slowly recovering and the company will be comparing against quarters last year when many Asian economies were at their low points. In Japan, the company is not counting on any economic improvement, but expects to continue to do reasonably well because of continuing demand for certain proprietary 3M products. In Latin America, the volume picture is expected to improve as the year progresses. Latin America is expected to show continuing good growth in Mexico, along with gradual improvement in Brazil and Argentina. In Europe, comparisons will become easier in the coming quarters. While European economies are growing slowly, 3M anticipates slightly better growth than in the first quarter.

The company is not able to project what the consequences will be from the turmoil in various economies around the world. The company is monitoring business conditions closely and is prepared to make adjustments in costs, pricing and investments as appropriate.

Based on currency rates at the end of April 1999, the company estimates that currency would reduce international sales for the year by about 3 percent and would negatively impact earnings per share by 8 cents for the full year.

Capital spending totaled \$1.430 billion in 1998, and is expected to be in line with the company's target of \$1.2 billion for 1999. The company does not expect a significant change in its tax rate in 1999.

YEAR 2000 READINESS

The Year 2000 issue is the result of using only the last two digits to indicate the year in computer hardware and software programs and embedded technology such as micro-controllers. As a result, these programs do not properly recognize a year that begins with "20" instead of the familiar "19." If uncorrected, such programs will be unable to interpret dates beyond the year 1999, which could cause computer system failure or other errors disrupting normal business operations.

The company recognizes the importance of readiness for the Year 2000 and has given it high priority. In November 1996, the company created a corporate-wide Year 2000 project team representing all company business and staff units. The team's objective is to ensure an uninterrupted transition to the year 2000 by assessing, testing and modifying IT and non-IT systems (defined below) and date-sensitive company products so that (a) they will perform as intended, regardless of the date (before, during and after December 31, 1999), and (b) dates (before, during and after December 31, 1999 and including February 29, 2000) can be processed with expected results ("Year 2000 Compliant"). The scope of the Year 2000 compliance effort includes (i) information technology ("IT") such as software and hardware; (ii) non-IT systems or embedded technology such as micro-controllers contained in various manufacturing and laboratory equipment; environmental and safety systems, facilities and utilities, (iii) date-sensitive company products; and (iv) the readiness of key third parties, including suppliers and customers, and the electronic data interchange (EDI) with those key third parties.

The Year 2000 project team has taken an inventory of IT and non-IT systems and date-sensitive company products that might malfunction or fail as a result of using only the last two digits to indicate the year. The project teams then categorized the potential date component failures into three categories: "Vital" (stops the business operation and no short-term solution is available); "Critical" (inconvenient to the business operation and a short-term solution is available); and "Marginal" (inconsequential to the business operation).

IT Systems - The company is using both internal and external resources to remediate and test millions of lines of application software code. As of March 31, 1999, approximately (i) 98 percent of the core central IT application systems (e.g., general ledger, payroll, procurement and order management), (ii) 92 percent of central IT infrastructure systems (e.g., telecommunications, electronic mail, databases, data centers, and system software), and (iii) 84 percent of the other IT systems (e.g., systems that support business and staff organizations) located in the United States that are deemed "Vital" or "Critical" are believed to be Year 2000 Compliant. As of March 31, 1999, approximately 98 percent of the IT systems in subsidiaries outside the United States that are deemed "Vital" or "Critical" are believed to be Year 2000 Compliant.

Non-IT Systems - The company has more than 100 manufacturing and laboratory locations worldwide with varying degrees of non-IT systems (such as programmable logic controllers, gauging guidance and adjustment systems and testing equipment). Assessment and testing of non-IT systems for Year 2000 compliance has proven much more difficult than assessing compliance of IT systems because testing of non-IT systems often requires shutdown of the manufacturing operations.

As a result, the company has approached assessment and testing of non-IT systems that are common to many of the company's facilities by (i) contacting the suppliers of these non-IT systems and obtaining statements that the systems are Year 2000 Compliant, and (ii) testing components of non-IT systems when they are shut down for normal maintenance. The company has also shut down manufacturing lines in three of its facilities and tested non-IT systems that are common to many of the company's facilities. These tests demonstrate that "time intervals" instead of "dates" are used almost exclusively in these non-IT systems and support the company's belief that potential disruptions of such systems due to the Year 2000 issue should be minimal.

As of March 31, 1999, approximately 93 percent of the non-IT systems located in the United States that are deemed "Vital" or "Critical" and approximately 97 percent of the non-IT systems in subsidiaries outside the United States that are deemed "Vital" or "Critical" are believed to be Year 2000 Compliant.

Company Products - The vast majority of the company's products are not date-sensitive. The company has collected information on current and discontinued date-sensitive products. The company's website (<http://www.3M.com>) contains a section dedicated to communicating year 2000 information to its customers. This website includes a search feature to enable customers to determine whether certain 3M products are Year 2000 compliant.

Third Parties - In addition to internal Year 2000 IT and non-IT remediation activities, the company is in contact with key suppliers, contract manufacturers and electronic commerce customers to minimize potential disruptions in the relationships between the company and these important third parties related to the Year 2000 issue. The assessment process includes (i) initial survey, (ii) risk assessment and contingency planning, and (iii) follow-up reviews.

The company has also categorized supplies purchased from vendors into three categories: "Vital" (disruption of supply stops the business operation and no short-term solution is available); "Critical" (disruption of supply is inconvenient to the business operation and a short-term solution is available); and "Marginal" (disruption of supply is inconsequential to the business operation). The company has focused its efforts on those vendors that supply goods or services deemed "Vital" to the company's business. The company has received responses to its initial year 2000 readiness survey from most of its

"Vital" suppliers indicating that the suppliers are working on the year 2000 issue. While the company cannot guarantee compliance by third parties, the company is developing contingency plans with its key suppliers that include the availability of appropriate inventories of supplies in the event the supplier is not Year 2000 Compliant.

Risks and Worst Case Scenarios - The company believes that its most reasonably likely worst case scenarios regarding the year 2000 issue involves the IT and non-IT systems of third parties rather than the IT and non-IT systems and products of the company. Because the company has far less control over assessing the year 2000 readiness of certain third parties, the company believes the risks are greatest with suppliers of electrical, telecommunications, and transportation services, particularly suppliers of such services located outside the United States. Contingency planning regarding the failure of such services involves maintaining appropriate inventories of key raw materials and products.

Contingency Planning - The company is preparing contingency plans specifying what the company will do if failures occur in IT and non-IT systems, or important third parties are not Year 2000 Compliant. The process includes identifying and prioritizing risks, assessing the business impact of those risks, creating notification procedures, and preparing written contingency plans for those failures with the greatest risk to the company. As of March 31, 1999, the company's contingency plans were 75% complete for its IT and non-IT systems and 100% complete for its key suppliers.

Costs - Through March 31, 1999, the company had spent approximately \$55 million out of a total estimate of \$77 million related to Year 2000 readiness issue. These costs include the costs incurred for external consultants and professional advisors and the costs for software and hardware. The company's process for tracking internal costs does not capture all of the costs incurred for each of the teams working on the Year 2000 project. Such internal costs are principally the related payroll costs for its information systems group and other employees working on the Year 2000 project. The company is expensing as incurred all costs related to the assessment and remediation of the Year 2000 issue. These costs are being funded through operating cash flows.

The company's current estimates of the time and costs necessary to remediate and test its computer systems are based on the facts and circumstances existing at this time. The estimates were made using assumptions of future events including the continued availability of certain resources, such as skilled IT personnel and infrastructure (e.g., electrical supply and water and sewer service), telecommunications, transportation supply chains, critical suppliers of materials, and Year 2000 modification plans and implementation success by key third-parties. New developments could affect the company's estimates of the amount of time and costs needed to modify and test its IT and non-IT systems for Year 2000 compliance and, depending on the year 2000 readiness of certain third parties, could

affect the company's ability to conduct its business. These developments include, but are not limited to: (i) the availability and cost of personnel trained in this area; (ii) the ability to locate and correct all relevant date-sensitive code in both IT and non-IT systems; (iii) unanticipated failures in IT and non-IT systems; (iv) the planning and Year 2000 compliance success that key customers and suppliers attain; (v) failure or collapse of infrastructure (e.g., disruptions of electrical supply and water and sewer service), telecommunications, transportation supply chains, and critical suppliers of materials, particularly those suppliers of such services and goods located outside the United States; (vi) unforeseen product shortages due to hoarding of critical raw materials.

The company cannot determine the impact of these potential developments on the current estimate of probable costs of making its products and IT and non-IT systems Year 2000 Compliant or the financial impact on the company. Accordingly, the company is not able to estimate possible future costs beyond the current estimates. As new developments occur, these cost estimates may be revised to reflect the impact of these developments on the costs to the company of making its products and IT and non-IT systems Year 2000 Compliant. Such cost revisions could have a material adverse impact on the company's net income in the quarterly period in which they are recorded. Although the company considers it unlikely, such revisions could also have a material adverse effect on the consolidated financial position or annual results of operations of the company.

Various of the company's disclosures and announcements concerning its products and year 2000 programs are intended to constitute "Year 2000 Readiness Disclosures" as defined in the recently enacted Year 2000 Information and Readiness Disclosure Act. The Act provides added protection from liability for certain public and private statements concerning an entity's year 2000 readiness and the year 2000 readiness of its products and services. The Act also potentially provides added protection from liability for certain types of year 2000 disclosures made after January 1, 1996 and before the date of enactment of the Act.

THE EURO CONVERSION

On January 1, 1999, 11 of the 15 member countries of the European Union (EU) established fixed conversion rates through the European Central Bank (ECB) between existing local currencies and the euro, the EU's new single currency. The participating countries had agreed to adopt the euro as their common legal currency on that date. From that date, the euro is traded on currency exchanges and is available for non-cash transactions.

Following introduction of the euro, local currencies will remain legal tender until December 31, 2001. During this transition period, goods and services may be paid for with the euro or the local currency under the EU's "no compulsion, no prohibition" principle. If cross-border payments are made in a local currency during this transition period, the amount will be converted into euros and then converted from euros into the second local currency at rates fixed by

the ECB. By no later than December 31, 2001, the participating countries will issue new euro-denominated bills and coins for use in cash transactions. By no later than July 1, 2002, participating countries will withdraw all bills and coins denominated in local currencies, making the euro conversion complete.

In February 1997, the company created a European Monetary Union (EMU) Steering Committee and project teams representing all company business and staff units in Europe. The common objective of these teams is to ensure a smooth transition to EMU for the company and its constituencies. The scope of the teams' efforts includes (i) assessing the euro's impact on the company's business and pricing strategies for customers and suppliers, and (ii) ensuring that the company's business processes and information technology (IT) systems can process transactions in euros and local currencies during the transition period and achieve the conversion of all relevant local currency data to the euro by December 31, 2001, in the participating countries.

The European market contributed 26% of consolidated sales and 20% of consolidated operating income, excluding the restructuring charge, in 1998. The company believes that the euro will, over time, increase price competition for the company's products across Europe due to cross-border price transparency. The company also believes that the adverse effects of increased price competition will be offset somewhat by new business opportunities and efficiencies. The company, however, is not able to estimate the anticipated net long-term impact of the euro introduction on the company.

The company has consolidated IT operations and made significant investments in IT systems in Europe in anticipation of the EMU. The company expects that these investments will enable the company to manage customer orders, invoices, payments and accounts in euros and in local currencies according to customer needs during the three-year transition period. During this period, the company anticipates spending approximately \$35-50 million to complete the conversion to the euro. Because the company believes its IT systems will be ready by December 31, 2001 for the euro conversion, it has not developed contingency plans at this time.

The euro introduction is not expected to have a material impact on the company's overall currency risk. Although the company engages in significant trade within the EU, the impact to date of changes in currency exchange rates on trade within the EU has not been material. The company anticipates the euro will simplify financial issues related to cross-border trade in the EU and reduce the transaction costs and administrative time necessary to manage this trade and related risks. The company believes that the associated savings will not be material to corporate results.

The company has derivatives outstanding beyond January 1, 1999, in several European currencies. Under the EU's "no compulsion, no prohibition" principle, the outstanding derivative positions will either mature as local currency contracts or convert to euro contracts at no additional economic cost to the company. The company

believes that systems used to monitor derivative positions can be appropriately modified for these changes. The company believes the impact of the euro introduction on the company's derivative positions will not be material.

FORWARD-LOOKING STATEMENTS

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. This Quarterly Report on Form 10-Q contains forward-looking statements, which reflect the company's current views with respect to future events and financial performance.

These forward-looking statements are subject to certain risks and uncertainties, including those identified here, which could cause actual results to differ materially from historical results or those anticipated. The words "aim," "believe," "expect," "anticipate," "intend," "estimate," "will," "should," "could" and other expressions that indicate future events and trends identify forward-looking statements.

Actual future results and trends may differ materially from historical results or those anticipated depending on a variety of factors, including, but not limited to: foreign exchange rates and fluctuations in those rates; the effects of, and changes in, worldwide economic conditions; the timing and market acceptance of new product offerings; raw materials, including shortages and increases in the costs of key raw materials; the impact of the Year 2000 issue; and legal proceedings (see discussion of Legal Proceedings in Part II, Item 1 of this Form 10-Q).

FINANCIAL CONDITION AND LIQUIDITY

The company's financial condition and liquidity remain strong.

Working capital increased \$142 million to \$2.074 billion at March 31, 1999, compared with \$1.932 billion at year-end 1998. The accounts receivable average days' sales outstanding was 60 days, down slightly from year-end. The company's key inventory index was 3.3 months, down from 3.4 months at year-end. The company's current ratio was 1.5, up from 1.4 at year-end.

Total debt decreased \$386 million from year-end 1998 to \$2.720 billion. As of March 31, 1999, total debt was 31 percent of total capital.

The company's strong credit rating provides ready and ample access to funds in global capital markets. At March 31, 1999, the company had available short-term lines of credit totaling about \$670 million.

Net cash provided by operating activities totaled \$828 million in the first three months of the year, up \$453 million from the same period last year. The first quarter of 1999 was helped by good working capital management. Inventories declined by about \$390 million, or 16 percent, when compared to the first quarter of 1998. Working capital and other changes in 1999 include a \$65 million use of cash for the

impact of the employee termination benefits paid in connection with the restructuring charge. Net cash outflows from mammary implant litigation were \$61 million lower than in the same period last year. During the second quarter of 1999, the company expects to receive more than \$200 million of insurance recoveries related to product claims.

Timing differences between payment of implant liabilities and receipt of related insurance recoveries could affect the cash flows of future periods. This is discussed in Part II, Item 1, Legal Proceedings, of this Form 10-Q.

Cash used in investing activities was \$329 million in the first three months of the year, compared with \$401 million in the same period last year. Capital expenditures for the first three months of 1999 were \$289 million, a decrease of about 15 percent when compared with the same period last year. The company expects to receive cash proceeds (net of tax) in the second or third quarter of 1999 of approximately \$185 million relating to its pending divestitures of Eastern Heights Bank and the Cardiovascular Systems business.

Treasury stock repurchases for the first three months of 1999 were \$32 million, compared with repurchases in the same period last year of \$187 million. Financing activities for both short-term and long-term debt provided net cash outflows of \$240 million, compared with net cash inflows of \$258 million in the first three months last year.

The company repurchased about 400,000 shares of common stock in the first three months of 1999, compared with 2.2 million shares in the same period last year. In February 1999, the Board of Directors authorized the repurchase of up to 12 million shares of 3M common stock through December 31, 1999. As of March 31, 1999, 11.6 million shares remained authorized for repurchase. Stock repurchases are made to support employee stock purchase plans and for other corporate purposes.

Cash dividends paid to shareholders totaled \$225 million in the first three months of this year, compared with \$222 million in the same period last year. In February 1999, the quarterly dividend was increased to 56 cents a share.

Legal proceedings are discussed in the Legal Proceedings section in Part II, Item 1, of this Form 10-Q. There can be no certainty that the company may not ultimately incur charges, whether for governmental proceedings and claims, products liability claims, environmental proceedings or other actions, in excess of presently established accruals. While such future charges could have a material adverse impact on the company's net income in the quarterly period in which they are recorded, the company believes that such additional charges, if any, would not have a material adverse effect on the consolidated financial position or annual results of operations of the company. (NOTE: The preceding sentence applies to all legal proceedings involving the company except the breast implant litigation. See discussion of breast implant litigation in Legal Proceedings, Part II, Item 1.)

Item 1. Legal Proceedings

The company and certain of its subsidiaries are named as defendants in a number of actions, governmental proceedings and claims, including environmental proceedings and products liability claims involving products now or formerly manufactured and sold by the company. In some actions, the claimants seek damages as well as other relief, which, if granted, would require substantial expenditures. The company has accrued certain liabilities, which represent reasonable estimates of its probable liabilities for these matters. The company also has recorded receivables for the probable amount of insurance recoverable with respect to these matters.

Some of these matters raise difficult and complex factual and legal issues, and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular action, the jurisdiction and forum in which each action is proceeding and differences in applicable law. Accordingly, the company is not always able to estimate the amount of its possible future liabilities with respect to such matters.

There can be no certainty that the company may not ultimately incur charges, whether for governmental proceedings and claims, products liability claims, environmental proceedings or other actions, in excess of presently established accruals. While such future charges could have a material adverse impact on the company's net income in the quarterly period in which they are recorded, the company believes that such additional charges, if any, would not have a material adverse effect on the consolidated financial position or annual results of operations of the company. (NOTE: The preceding sentence applies to all legal proceedings involving the company except the breast implant litigation, which is discussed separately in the next section).

Breast Implant Litigation

As of March 31, 1999, the company had been named as a defendant, often with multiple co-defendants, in 5,488 lawsuits and 121 claims in various courts, all seeking damages for personal injuries from allegedly defective breast implants. These claims and lawsuits purport to represent 20,060 individual claimants. It is not yet certain how many of these lawsuits and claims involve products manufactured and sold by the company, as opposed to other manufacturers, or how many of these lawsuits and claims involve individuals who accepted benefits under the Revised Settlement Program (as defined below). The company has confirmed that approximately 1,000 individuals who opted out of the class action have 3M implants. The company entered the business of manufacturing breast implants in 1977 by purchasing McGhan Medical Corporation. In 1984, the company sold the business to a corporation that also was named McGhan Medical Corporation.

The typical claim or lawsuit alleges the individual's breast implants caused one or more of a wide variety of ailments and local complications, including, but not limited to, non-specific autoimmune disease, scleroderma, lupus, rheumatoid arthritis, fibromyalgia, mixed connective tissue disease, Sjogren's Syndrome, dermatomyositis, polymyositis and chronic fatigue.

Plaintiffs in these cases typically seek monetary damages, often in unspecified amounts, and also may seek certain types of equitable relief, including requiring the company to fund the costs associated with removal of the breast implants.

A number of breast implant claims and lawsuits seek to impose liability on the company under various theories for personal injuries allegedly caused by breast implants manufactured and sold by manufacturers other than the company. These manufacturers include, but are not limited to, McGhan Medical Corporation and manufacturers that are no longer in business or that are insolvent, whose breast implants may or may not have been used in conjunction with implants manufactured and sold by the company. These claims raise many difficult and complex factual and legal issues that are subject to many uncertainties, including the facts and circumstances of each particular claim, the jurisdiction in which each suit is brought, and differences in applicable law and insurance coverage.

A number of breast implant lawsuits seek to recover punitive damages. Any punitive damages that may be awarded against the company may or may not be covered by certain insurance policies depending on the language of the insurance policy, applicable law and agreements with insurers.

In addition to individual suits against the company, a class action on behalf of all women with breast implants filed against all manufacturers of such implants has been conditionally certified and is pending in the United States District Court for the Northern District of Alabama (the "Court")(DANTE, ET AL., V. DOW CORNING, ET AL., U.S.D.C., N. Dist., Ala., 92-2589; part of IN RE: SILICONE GEL BREAST IMPLANT PRODUCT LIABILITY LITIGATION, U.S.D.C., N. Dist. Ala., MDL 926, U.S.D.C., N. Dist. Ala., CV 92-P-10000-S; now held in abeyance pending settlement proceedings in the settlement class action LINDSEY, ET AL., V. DOW CORNING CORPORATION, ET AL., U.S.D.C., N. Dist., Ala., CV 94-P-11558-S). Class actions, some of which have been certified, are pending in various state courts, including, among others, Louisiana, Florida and Illinois, and in the British Columbia courts in Canada. The Louisiana state court action (SPITZFADEN, ET AL., v. DOW CORNING CORPORATION, ET AL., Dist. Ct., Parish of Orleans, 92-2589) has been decertified by the trial court. Plaintiffs' writ for an emergency appeal from the decertification has been denied by the Louisiana Supreme Court. A normal appeal remains pending.

The company also has been served with a purported class action brought on behalf of children allegedly exposed to silicone in utero and through breast milk. (FEUER, ET AL., V. MCGHAN, ET AL., U.S.D.C., E. Dist. NY, 93-0146.) The suit names all breast implant manufacturers as defendants and seeks to establish a medical- monitoring fund.

On December 22, 1995, the Court approved a revised class action settlement program for resolution of claims seeking damages for personal injuries from allegedly defective breast implants (the "Revised Settlement Program"). The Revised Settlement Program is a revision of a previous settlement pursuant to a Breast Implant Litigation Settlement Agreement (the "Settlement Agreement") reached on April 8, 1994, and approved by the Court on September 1, 1994.

The Court ordered that, beginning after November 30, 1995, members of the plaintiff class may choose to participate in the Revised Settlement Program or opt out, which would then allow them to proceed with separate products liability actions.

The Revised Settlement Program includes domestic class members with implants manufactured by certain manufacturer defendants, including Baxter International, Bristol-Myers Squibb Company, the company and McGhan Medical Corporation. The company's obligations under the Revised Settlement Program are limited to eligible claimants with implants manufactured by the company or its predecessors ("3M implants") or manufactured only by McGhan Medical Corporation after its divestiture from the company on August 3, 1984 ("Post 8/84 McGhan implants"). With respect to claimants with only Post 8/84 McGhan implants (or only Post 8/84 McGhan implants plus certain other manufacturers' implants), the benefits are more limited than for claimants with 3M implants. Post 8/84 McGhan implant benefits are payable in fixed shares by the company, Union Carbide Corporation and McGhan Medical Corporation. McGhan Medical Corporation has defaulted on its fixed share obligation (which does not affect 3M's obligation to pay its share) and has a request for a mandatory class action recently approved by the Court.

In general, the amounts payable to individual current claimants (as defined in the Court's order) under the Revised Settlement Program, and the company's obligations to make those payments, are not affected by the number of class members who have elected to opt out of the Revised Settlement Program or the number of class members making claims under the Revised Settlement Program. In addition to certain miscellaneous benefits, the Revised Settlement Program provides for two compensation options for current claimants with 3M implants.

Under the first option, denominated as Fixed Amount Benefits, current claimants with 3M implants who satisfy disease criteria established in the prior Settlement Agreement will receive amounts ranging from \$5,000 to \$100,000, depending on disease severity or disability level; whether the claimant can establish that her implants have ruptured; and whether the claimant also has had implants manufactured

by Dow Corning. Under the second option, denominated as Long-Term Benefits, current claimants with 3M implants who satisfy more restrictive disease and severity criteria specified under the Revised Settlement Program can receive benefits ranging from \$37,500 to \$250,000.

In addition, current claimants with 3M implants are eligible for (a) a one-time payment of \$3,000 upon removal of 3M implants during the course of the class settlement, and (b) an advance payment of \$5,000 against the above referenced benefits upon proof of having 3M implants and upon waiving or not timely exercising the right to opt out of the Revised Settlement Program. Current claimants with only Post 8/84 McGhan implants (or only Post 8/84 McGhan implants plus certain other manufacturers' implants) are eligible only for benefits ranging from \$10,000 to \$50,000.

Eligible participants with 3M implants who did not file current claims but are able to satisfy the more restrictive disease and severity criteria during an ongoing period of 15 years will be eligible for the Long-Term Benefits, subject to certain funding limitations. Such participants also will be eligible for an advance payment of \$1,000 upon proof of having 3M implants and upon waiving or not timely exercising the right to opt out of the Revised Settlement Program or, as an elective option expiring on June 15, 1999, a payment of \$3,500 in full settlement of all breast implant claims including any claim for Long-Term Benefits under the Revised Settlement Program. Benefit levels for eligible participants who are not current claimants and have only Post 8/84 McGhan implants (or only Post 8/84 McGhan implants plus certain other manufacturers' implants) will range from \$10,000 to \$50,000.

On June 10, 1998 the Court approved the terms of a settlement program offered by Baxter International, Bristol-Myers Squibb Company and the company to eligible foreign implant recipients (the "Foreign Settlement Program"). Notices and claim forms were mailed on June 15, 1998. Benefits to eligible foreign claimants range from \$3,500 to \$50,000.

As of the date of this filing, the company believes that approximately 90% of the registrants, including those claimants who filed current claims, have elected to participate in the Revised Settlement Program. It is still unknown as to what disease criteria all claimants have satisfied, and what options they have chosen. As a result, the total amount and timing of the company's prospective payments under the Revised Settlement Program cannot be determined with precision at this time. As of March 31, 1999, the company has paid \$232 million into the court-administered fund as a reserve against costs of claims payable by the company under the Revised Settlement Program (including a \$5 million administrative assessment). Additional payments will be made as necessary. Payments to date have been consistent with the company's estimates of the total liability for these claims.

In the first quarter of 1994, the company took a pre-tax charge of \$35 million (\$22 million after tax) in recognition of its then best estimate of its probable liabilities and associated expenses, net of the probable amount of insurance recoverable from its carriers. In the second quarter of 1998, the company increased its estimate of the minimum probable liabilities and associated expenses to approximately \$1.1 billion, with an offsetting increase in the probable amount of insurance recoveries. This amount represents the company's best estimate of the minimum amount to cover the cost and expense of the Revised Settlement Program and the cost and expense of resolving opt-out claims and recovering insurance proceeds. After subtracting payments of \$1.007 billion as of March 31, 1999, for defense and other costs and settlements with litigants and claimants, the company had accrued liabilities of \$93 million.

The company has substantial primary and excess products liability occurrence insurance coverage and claims-made products liability insurance coverage, which it believes provide coverage for substantially all of its current exposure for breast implant claims and defense costs. Most insurers have alleged reservations of rights to deny all or part of the coverage for differing reasons, including each insurer's obligations in relation to the other insurers (i.e. allocation) and which claims trigger both the various occurrence and claims-made insurance policies. Some insurers have resolved and paid, or committed to, their policy obligations. The company believes the failure of many insurers to voluntarily perform as promised subjects them to the company's claims for excess liability and damages for breach of the insurers' obligation of good faith.

On September 22, 1994, three excess coverage occurrence insurers initiated in the courts of the State of Minnesota a declaratory judgment action against the company and numerous insurance carriers seeking adjudication of certain coverage issues and allocation among insurers. On December 9, 1994, the company initiated an action against its occurrence insurers in the Texas State Court in and for Harrison County, seeking a determination of responsibility among the company's various occurrence insurers with applicable coverages. The state of Texas has the most implant claims. This action has since been removed to the U.S. District Court, Eastern District of Texas, and stayed pending resolution of the litigation in the Minnesota courts.

The insurers that are parties to these actions generally acknowledge that they issued products liability insurance to the company and that breast implant claims are products liability claims. The trial in Minnesota to resolve the company's insurance coverage and the financial responsibility of occurrence insurers for breast implant claims and defense costs began on June 4, 1996, and is continuing in phases. The most recent phases were completed on January 20, 1999 and March 31, 1999.

In mid-October 1995, the occurrence insurers that are parties to the litigation in Minnesota filed more than 30 motions for summary judgment or partial summary judgment. The insurers, through these motions, attempted to shift all or a portion of the responsibility for those claims the company believes fall within the period of occurrence-based coverage (before 1986) into the period of claims-made coverage (from and after 1986). The trial court denied the insurers' motions, ruling that the key issues of trigger and allocation raised in these motions would be resolved at trial. In the trial's first phase in 1996, the court granted 3M partial declaratory judgment on the question of when insurance coverage is "triggered." The court also granted the insurers' motion for partial declaratory judgment on the question of the allocation method to be applied in the case. In July 1997, the trial court ruled further on the trigger issue and on the general allocation method. That ruling was consistent with and further supported the company's opinion as stated in the following paragraph. In November 1997, upon reconsideration, the court reversed a portion of its July ruling and reinstated a portion of its previous ruling. The company believed that conflicting rulings existed that needed to be clarified by the court and reconciled with applicable law. Motions to clarify the allocation methodology of triggered policies under these rulings were filed and have been ruled upon by the Court. While the Court clarified certain aspects of these rulings it also ruled that there would be no allocation from and after 1986. This ruling is consistent with the company's position on the allocation issue.

The company believes it ultimately will prevail in this insurance litigation. The company's belief is based on an analysis of its insurance policies; court decisions on these and similar issues; reimbursement by insurers for these types of claims; and consultation with outside counsel who are experts in insurance coverage matters. If, however, the occurrence insurers ultimately prevail in this insurance litigation, the company could be effectively deprived of significant and potentially material insurance coverage for breast implant claims. (See discussion of the accrued receivables for insurance recoveries below.)

As of March 31, 1999, the company had accrued receivables for insurance recoveries of \$750 million, substantially all of which is contested by the insurance carriers. During the first quarter of 1999 the company executed a settlement agreement with its lead occurrence underwriter. The first payment of settlement dollars was received on April 14, 1999, with additional and final payments to be made no later than June 15, 1999. Various factors could affect the timing and amount of proceeds to be received under the company's various insurance policies, including (i) the timing of payments made in settlement of claims; (ii) the outcome of occurrence insurance litigation in the courts of Minnesota (as discussed above) and Texas; (iii) potential arbitration with claims-made insurers; (iv) delays in payment by insurers; and (v) the extent to which insurers may become insolvent in the future. There can be no absolute assurance that the company will collect all amounts accrued as being probable of recovery from its insurers.

The company's current estimate of the probable liabilities, associated expenses and probable insurance recoveries related to the breast implant claims is based on the facts and circumstances existing at this time. New developments may occur that could affect the company's estimates of probable liabilities (including associated expenses) and the probable amount of insurance recoveries. These developments include, but are not limited to, (i) the ultimate Fixed Amount Benefit distribution to claimants in the Revised Settlement Program; (ii) the success of and costs to the company in defending opt-out claims, including claims involving breast implants not manufactured or sold by the company; (iii) the outcome of the occurrence insurance litigation in the courts of Minnesota and Texas; and (iv) the outcome of potential arbitration with claims-made insurers.

The company cannot determine the impact of these potential developments on the current estimate of probable liabilities (including associated expenses) and the probable amount of insurance recoveries. Accordingly, the company is not able to estimate its possible future liabilities and recoveries beyond the current estimates of probable amounts. As new developments occur, these estimates may be revised, or additional charges may be necessary to reflect the impact of these developments on the costs to the company of resolving breast implant litigation, claims and insurance recoveries. Such revisions or additional future charges could have a material adverse impact on the company's net income in the quarterly period in which they are recorded. Although the company considers it unlikely, such revisions or additional future charges could also have a material adverse effect on the consolidated financial position or annual results of operations of the company.

The company conducts ongoing reviews, assisted by outside counsel, to determine the adequacy and extent of insurance coverage provided by its occurrence and claims-made insurers. The company believes, based on these ongoing reviews and the bases described in the fourth preceding paragraph, it is probable that the collectible coverage provided by its applicable insurance policies is sufficient to cover substantially all of its current exposure for breast implant claims and defense costs. Based on the availability of this insurance coverage, the company believes that its uninsured financial exposure has not materially changed since the first quarter of 1994. Therefore, no recognition of additional charges has been made.

Environmental Matters

The company also is involved in a number of environmental proceedings by governmental agencies and by private parties asserting liability for past waste disposal and other alleged environmental damage. The company conducts ongoing investigations, assisted by environmental consultants, to determine accruals for the probable, estimable costs of remediation. The remediation accruals are reviewed each quarter and changes are made as appropriate.

Item 6. Exhibits and Reports on Form 8-K

(a) The following documents are filed as exhibits to this Report.

(12) A statement regarding the calculation of the ratio of earnings to fixed charges. Page 28.

(15) A letter from the company's independent auditors regarding unaudited interim consolidated financial statements. Page 29.

(27) Financial data schedule (EDGAR filing only).

None of the other item requirements of Part II of Form 10-Q are applicable to the company for the quarter ended March 31, 1999.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MINNESOTA MINING AND MANUFACTURING COMPANY
(Registrant)

Date: *May 6, 1999*

/s/ Giulio Agostini

*Giulio Agostini, Senior Vice President and
Chief Financial Officer*

*(Mr. Agostini is the Principal Financial
and Accounting Officer and has been duly
authorized to sign on behalf of the
registrant.)*

MINNESOTA MINING AND MANUFACTURING COMPANY AND SUBSIDIARIES
 CALCULATION OF THE RATIO OF EARNINGS TO FIXED CHARGES
 (Dollars in millions)
 (Unaudited)

	Three Months					
	Ended					
	March 31,	Year	Year	Year	Year	Year
	1999	1998	1997	1996	1995	1994
	-----	-----	-----	-----	-----	-----
EARNINGS						
Income from continuing operations before income taxes, minority interest and extraordinary loss*	\$ 626	\$1,952	\$3,440	\$2,479	\$2,168	\$2,011
Add:						
Interest on debt	31	139	94	79	102	70
Interest component of the ESOP benefit expense	5	29	32	34	37	39
Portion of rent under operating leases representative of the interest component	10	41	41	46	51	46
Less: Equity in undistributed income of 20-50% owned companies	1	4	3	--	1	2
	-----	-----	-----	-----	-----	-----
TOTAL EARNINGS AVAILABLE FOR FIXED CHARGES	\$ 671	\$2,157	\$3,604	\$2,638	\$2,357	\$2,164
	=====	=====	=====	=====	=====	=====
FIXED CHARGES						
Interest on debt	31	139	94	79	102	70
Interest component of the ESOP benefit expense	5	29	32	34	37	39
Portion of rent under operating leases representative of the interest component	10	41	41	46	51	46
	-----	-----	-----	-----	-----	-----
TOTAL FIXED CHARGES	\$ 46	\$ 209	\$ 167	\$ 159	\$ 190	\$ 155
	=====	=====	=====	=====	=====	=====
RATIO OF EARNINGS TO FIXED CHARGES	14.59	10.32	21.58	16.59	12.41	13.96

<F1>
 *1998 includes a pre-tax restructuring charge of \$493 million; 1997 includes a pre-tax gain on the sale of National Advertising Company of \$803 million; 1995 includes a pre-tax restructuring charge of \$79 million.

EXHIBIT 15

Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549

Commissioners:

We are aware that our report dated May 5, 1999, on our reviews of interim consolidated financial information of Minnesota Mining and Manufacturing Company and Subsidiaries (the Company) for the three- month periods ended March 31, 1999 and 1998, and included in the Company's Form 10-Q for the quarter ended March 31, 1999, is incorporated by reference in the Company's registration statements on Form S-8 (Registration Nos. 33-14791, 33-49842, 33-58767, 333-26957, 333-30689 and 333-30691), and Form S-3 (Registration No. 33-48089).

/s/ PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP

*St. Paul, Minnesota
May 6, 1999*

ARTICLE 5

THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE CONSOLIDATED STATEMENT OF INCOME AND CONSOLIDATED BALANCE SHEET AND RELATED NOTES AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH CONSOLIDATED FINANCIAL STATEMENTS AND NOTES.

MULTIPLIER: 1,000,000

PERIOD TYPE	3 MOS
FISCAL YEAR END	DEC 31 1999
PERIOD END	MAR 31 1999
CASH	253
SECURITIES	98
RECEIVABLES	2,647
ALLOWANCES	0
INVENTORY	2,092
CURRENT ASSETS	966
PP&E	13,275
DEPRECIATION	7,759
TOTAL ASSETS	13,746
CURRENT LIABILITIES	3,982
BONDS	1,569
PREFERRED MANDATORY	0
PREFERRED	0
COMMON	236
OTHER SE	5,733
TOTAL LIABILITY AND EQUITY	13,746
SALES	3,776
TOTAL REVENUES	3,776
CGS	2,162
TOTAL COSTS	2,162
OTHER EXPENSES	0
LOSS PROVISION	0
INTEREST EXPENSE	31
INCOME PRETAX	626
INCOME TAX	225
INCOME CONTINUING	384
DISCONTINUED	0
EXTRAORDINARY	0
CHANGES	0
NET INCOME	384
EPS PRIMARY	.95
EPS DILUTED	.95

End of Filing

Powered By **EDGAR**
Online

© 2005 | EDGAR Online, Inc.